CoChat

A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis

Open access
Atassi, Nazem, Ratai, Eva-Maria, Greenblatt, David J., Pulley, Darlene, Zhao, Yanli, Bombardier, Jeffery, Wallace, Stuart, Eckenrode, Joanna, Cudkowicz, Merit, Dibernardo, Allitia · 2010 · Amyotrophic Lateral Sclerosis
Cited by 37

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Nazem Atassi*a, Eva-Maria Rataia, David J. Greenblattb, Darlene Pulleya, Yanli Zhaob, Jeffery Bombardiera, Stuart Wallacea, Joanna Eckenrodea, Merit Cudkowicza & Allitia Dibernardoaa Massachusetts General Hospitalb Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine and Tufts Medical Center, Boston, USACorrespondence: N. Atassi, Massachusetts General Hospital, Neurology Clinical Trials Unit (NCTU), 13th Street, Building 149, Room 2274, Charlestown, Massachusetts 02129, USA. Fax: 617 7247290. E-mail: NATASSI@PARTNERS.ORGAbstractCreatine monohydrate (creatine) has potential neuroprotective properties and is a commonly used supplement in amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Minimum therapeutic and maximum tolerated dosages of creatine are not yet known, nor is it known what systemic plasma concentrations result from specific dosage regimens. The objectives of this study were to establish steady-state plasma pharmacokinetics of creatine at several dosages, and to evaluate the effects of creatine on brain metabolites using proton magnetic resonance spectroscopy (1H-MRS). Six participants with ALS received creatine at three weekly escalating oral dosages (5, 10, and 15 g b.i.d.). Plasma creatine levels and MR spectra were obtained at baseline and with each dosage increase. Mean pre-dose steady-state creatine plasma concentrations were 20.3, 39.3, and 61.5 ug/ml at 5, 10, and 15 g b.i.d., respectively. Creatine spectra increased by 8% (p = 0.06) and glutamate + glutamine signals decreased by 17% (p = 0.039) at higher dosages. There were no safety concerns at any of the dosages. In conclusion, creatine plasma concentrations increased in a dose-dependent manner. Creatine appears to cross the blood-brain barrier, and oral administration of 15 g b.i.d. is associated with increased in vivo brain creatine concentrations and decreased glutamate concentrations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/17482961003797130

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 37

Metadata

Authors
Atassi, N., Ratai, E.-M., Greenblatt, D. J., Pulley, D., Zhao, Y., Bombardier, J., Wallace, S., Eckenrode, J., Cudkowicz, M., & Dibernardo, A.
Venue
Amyotrophic Lateral Sclerosis
Published
2010-08-11
Volume
11
Issue
6
Pages
508-513
ISSN
  • 1471-180X (ISSN-L)
  • 1748-2968
OpenAlex
W1972633070
Cited by
37
References
4
FWCI
2.08
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.3109/17482961003797130
The paper
Atassi, N., Ratai, E.-M., Greenblatt, D. J., Pulley, D., Zhao, Y., Bombardier, J., Wallace, S., Eckenrode, J., Cudkowicz, M., & Dibernardo, A. (2010). A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. https://doi.org/10.3109/17482961003797130

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.